These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33305817)

  • 1. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.
    Boof ML; Dingemanse J; Lederer K; Fietze I; Ufer M
    Sleep; 2021 Jun; 44(6):. PubMed ID: 33305817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea.
    Boof ML; Ufer M; Fietze I; Pépin JL; Guern AS; Lemoine V; Dingemanse J
    Sleep Med; 2022 Apr; 92():4-11. PubMed ID: 35306405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.
    Boof ML; Dingemanse J; Brunke M; Esselmann A; Heymer P; Kestermann O; Lederer K; Fietze I; Ufer M
    J Sleep Res; 2021 Aug; 30(4):e13248. PubMed ID: 33417730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
    Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD
    J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea.
    Cheng JY; Lorch D; Lowe AD; Uchimura N; Hall N; Shah D; Moline M
    J Clin Sleep Med; 2024 Jan; 20(1):57-65. PubMed ID: 37677076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
    Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
    Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.
    Zammit G; Dauvilliers Y; Pain S; Sebök Kinter D; Mansour Y; Kunz D
    Neurology; 2020 May; 94(21):e2222-e2232. PubMed ID: 32341187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
    Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
    Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
    Berger B; Brooks S; Zuiker R; Richard M; Muehlan C; Dingemanse J
    CNS Drugs; 2020 Dec; 34(12):1253-1266. PubMed ID: 33205362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
    Schilling U; Henrich A; Muehlan C; Krause A; Dingemanse J; Ufer M
    Clin Drug Investig; 2021 Aug; 41(8):711-721. PubMed ID: 34331678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
    Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
    CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
    Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J
    Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daridorexant in Insomnia Disorder: A Profile of Its Use.
    Nie T; Blair HA
    CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daridorexant for the treatment of insomnia disorder: findings and implications.
    Dos Santos JBR; da Silva MRR
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.
    Berger B; Kornberger R; Dingemanse J
    Eur Neuropsychopharmacol; 2021 Oct; 51():90-104. PubMed ID: 34098518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study.
    Cheng JY; Filippov G; Moline M; Zammit GK; Bsharat M; Hall N
    J Sleep Res; 2020 Aug; 29(4):e13021. PubMed ID: 32187781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia.
    Park J; Render PharmD KP; Cates PharmD DW
    Ann Pharmacother; 2023 Sep; 57(9):1076-1087. PubMed ID: 36602018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.